Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Payables (2023 - 2025)

Historic Payables for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $3.5 million.

  • BioLineRx's Payables fell 2365.64% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 2365.64%. This contributed to the annual value of $5.6 million for FY2024, which is 4863.37% down from last year.
  • BioLineRx's Payables amounted to $3.5 million in Q3 2025, which was down 2365.64% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Payables peaked at $10.9 million during Q4 2023, and registered a low of $3.5 million during Q2 2025.
  • Over the past 3 years, BioLineRx's median Payables value was $6.3 million (recorded in 2024), while the average stood at $6.3 million.
  • Over the last 5 years, BioLineRx's Payables had its largest YoY gain of 1569.51% in 2024, and its largest YoY loss of 4863.37% in 2024.
  • Quarter analysis of 3 years shows BioLineRx's Payables stood at $10.9 million in 2023, then crashed by 48.63% to $5.6 million in 2024, then tumbled by 36.65% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $3.5 million for Q2 2025, and $4.7 million during Q1 2025.